Eli Lilly And Co vs United Airlines Holdings Inc — how do they compare? Eli Lilly And Co trades at $1,218.42 (market cap $1.08T), while United Airlines Holdings Inc trades at $124.81 (market cap $41.00B). The key difference: Eli Lilly And Co is far larger — about 26.3× United Airlines Holdings Inc's market cap, and Eli Lilly And Co pays a 0.57% dividend while United Airlines Holdings Inc pays none. Which is the better fit depends on your goals.
| LLY | UAL | |
|---|---|---|
Market Cap | $1.08T | $41.00B |
Sector | Health | Industrials |
52-Week High | $1.24K | $136.11 |
52-Week Low | $639.43 | $85.21 |
Enterprise Value | $1.13T | $58.03B |
Dividend Yield | 0.57% | — |
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,221.21, down 0.84% today, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The stock shows technical strength with bullish moving averages and support at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 48% revenue growth in Q2 2026. Recent news highlights the company's aggressive protection of its obesity drug pipeline against black market sales.
LLY presents a compelling growth story with dominant market positioning in weight-loss drugs and strong analyst support (73% buy ratings). Key risks include regulatory scrutiny and competitive pressures, but the company's raised guidance and pipeline advancements support continued upside toward the $1,380 consensus target.
United Airlines (UAL) trades at $125.32, up 1.26% today, with strong technical momentum and consistent earnings beats. The stock shows bullish moving averages and trades near resistance at $126. Fundamentals are solid, with revenue growth to $59.07B in 2025 and net income of $3.35B, supported by a low P/E of 11.83. Recent news highlights fuel cost management and merger speculation, though operational disruptions pose near-term risks.
Outlook remains positive with a consensus price target of $167.73, implying 34% upside. Opportunities include robust travel demand and cost controls, but risks involve volatile fuel prices, competitive pressure, and execution challenges. Analyst sentiment is strongly bullish with 66% buy ratings, though investors should monitor margin sustainability amid economic uncertainties.
Trailing returns across standard periods
Latest headlines on both assets
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →United Airlines is a major U.S. network carrier. United's hubs include San Francisco, Chicago, Houston, Denver, Los Angeles, New York/Newark, and Washington, D.C. United operates a hub-and-spoke system that is more focused on international travel than legacy peers.
Read more on UAL →